Divis lab share price

NAME P/E (x) P/B (x) ROE % ROCE % ROA % Rev CAGR [3Yr] OPM NPM Basic EPS Current Ratio Total Debt/ Equity (x) Total Debt/ CFO (x) 52.14 7.45 14.28 17.76 12.62 13.12 30.50 23.47 68.69 8.46 0.00 0.00 28.80 3.40 12.10 17.78 9.61 9.84 19.03 12.46 34.72 3.38 0.02 0.00 17.75 3.44 19.35 25.95 13.96 12.22 24.94 18.12 271.47 2.41 0.06 0.00 50.36 10.04 20.08 22.79 8.29 6.17 22.66 12.94 36.79 0.98 0.85 0.00 28.36 2.82 11.19 16.43 7.61 6.57 19.28 11.58 19.30 1.81 0.07 0.00 Add More • Stock Returns vs Nifty 100 Stock gave a 3 year return of 49.29% as compared to Nifty 100 which gave a return of 83.77%. (as of last trading session) • Stock Returns vs Nifty Pharma Stock generated 49.29% return as compared to Nifty Pharma which gave investors 30.16% return over 3 year time period. (as of last trading session) Meeting Date Announced on Purpose Details May 20, 2023 May 12, 2023 Board Meeting Audited Results & Final Dividend Feb 03, 2023 Jan 23, 2023 Board Meeting Quarterly Results Nov 07, 2022 Oct 28, 2022 Board Meeting Quarterly Results Aug 22, 2022 Jul 04, 2022 AGM - Aug 12, 2022 Jul 28, 2022 Board Meeting Quarterly Results • All Types Ex-Date Record Date Announced on Details Bonus Sep 23, 2015 Sep 26, 2015 Aug 08, 2015 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Jul 30, 2009 Aug 01, 2009 Jun 06, 2009 Bonus Ratio: 1 share(s) for every 1 shares held Splits Aug 03, 2007 - May 23, 2007 Split: Old FV10.0| New FV:2.0 About Divis Labs Divi's Laboratories Ltd., incorporated in the year...

Divi's Laboratories Ltd. share price live 3,581.05, this page displays NS DIVI stock exchange data. View the DIVI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Divi's Laboratories Ltd. real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DIVI quote.

STOCK SUMMARY • Face Value (₹) 2.00 • Beta 0.33 • 52-Week Low (₹) 2,730.00 • 52-Week High (₹) 3,973.90 • Price-to-Book (X)* 7.44 • Dividend Yield (%) 0.84 • Price-to-Earnings (P/E) (X)* 52.12 • Earnings Per Share (₹) 68.69 • Sector Price Earning (X)* 30.00 • Market Cap (₹ Cr.)* 95,065.63 • * Vaues as of last close price COMPETITORS • Biocon ₹243.50 4.15 (1.73%) • Lupin ₹834.75 16.00 (1.95%) • Dr Reddys Laboratories ₹4,803.45 104.45 (2.22%) • Laurus Labs ₹366.75 7.75 (2.16%) • Ajanta Pharma ₹1,458.10 -17.55 (-1.19%) • Glaxosmithkline Pharmaceuticals ₹1,401.50 -10.70 (0.76%) • Torrent Pharmaceuticals ₹1,839.20 7.70 (0.42%) Divis Laboratories Limited is among India’s leading pharmaceutical companies. The firm is headquartered in Hyderabad, Andhra Pradesh. Divis Laboratories is primarily known for the production of active pharmaceutical ingredients (APIs) and intermediates. APIs are the key components in the manufacture of pharmaceutical products. Divis Laboratories had a humble beginning with a single research centre in Hyderabad. The company began its journey when scientist and entrepreneur Dr. Murali K. Divi founded Divi’s Research Center (DRC) in 1990. 1994 was the year when Divi’s Research Center rebranded and changed the company name to Divis Laboratories to mark its entry into the API manufacturing business. Divis Laboratories opened its first manufacturing facility near Hyderabad in 1995 and began production of APIs. 2002 was the year when operations were initiated at ...

15 Jun 3581.05 (2.73%) 14 Jun 3485.95 (-0.05%) 13 Jun 3487.70 (1.43%) 12 Jun 3438.45 (0.28%) 09 Jun 3428.75 (-2.03%) 08 Jun 3499.70 (-1.20%) 07 Jun 3542.10 (0.12%) 06 Jun 3537.90 (2.18%) 05 Jun 3462.30 (-1.40%) 02 Jun 3511.60 (-0.39%) 01 Jun 3525.40 (2.38%) 31 May 3443.60 (-0.42%) 30 May 3458.00 (-0.57%) 29 May 3477.85 (-1.03%) 26 May 3514.00 (2.28%) 25 May 3435.65 (1.55%) 24 May 3383.15 (-0.08%) 23 May 3385.80 (3.70%) 22 May 3265.00 (5.38%) 19 May 3098.30 (-1.75%) 18 May 3153.50 (-3.50%) Intraday Support and Resistance (Based on Pivot Points) | Updated On Jun 15, 2023 04:00 PM For Next Trading Session Pivots Classic Fibonacci Camarilla Woodie DM R3 3722.56 3656.78 3609.55 - - R2 3656.78 3617.19 3600.05 3663.76 - R1 3618.91 3592.72 3590.55 3632.87 3637.85 P 3553.13 3553.13 3553.13 3560.11 3562.6 S1 3515.26 3513.54 3571.55 3529.22 3534.2 S2 3449.48 3489.07 3562.05 3456.46 - S3 3411.61 3449.48 3552.55 - - Divis Laboratories Ltd Profit & Loss Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 INCOME 2291.95 2725.46 3399.24 3848.43 4180.05 4001.6 5406.48 5690.03 7110.63 9597.53 PROFIT 602.01 775.2 857.11 1128.59 1061.58 881.41 1353.05 1335.11 1986.75 2962.1 EPS 21.41 27.43 30.04 42.41 39.95 33.04 50.96 51.86 74.75 111.53 Divis Laboratories Ltd Profit & Loss Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 INCOME 2277.73 2711.61 3357.67 3793.98 4121.4 3947.8 5280.46 5594.53 6961.14 9441.07 PROFIT 61...

Divi’s Lab is undoubtedly one of the top pharma companies in India, Divis Laboratory is a privately owned research and development company specializing in the Divis Lab’s mission is to make quality medicines affordable to all, with a focus on ensuring access to essential medicines in developing countries and increasing the overall growth of the In this post, you will get to know about Divis Lab Share Price and company profile along with the key details such as products, founder, history, laboratories, and fundamentals. Contents • • • • • • • Divis Laboratories Ltd: Overview founded by Divi Murali Krishna Prasad in 1990. Divis Lab is headquartered in Hyderabad, India. The company has manufacturing facilities in India, the United States, and Europe. Divis Lab is a publicly traded company and its shares are listed on the Bombay Stock Exchange and the National Stock Exchange of India. Divis Lab has a market capitalization of approximately ₹87,268.81Cr. as of November 2022. Divi’s Laboratories Limited is a Company limited by shares, incorporated and domiciled in India. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceutical ingredients with a predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle ma...

• The company has shown a good profit growth of 30.305767947485% for the Past 3 years. • The company has shown a good revenue growth of 22.0873498246435% for the Past 3 years. • The company has significantly decreased its debt by 0.35 Cr. • Company has been maintaining healthy ROE of 23.6368973319846% over the past 3 years. • Company has been maintaining healthy ROCE of 30.6546127467123% over the past 3 years. • Company is virtually debt free. • Company has a healthy Interest coverage ratio of 2126.15606936416. • The Company has been maintaining an effective average operating margins of 37.7663024108421% in the last 5 years. • Company has a healthy liquidity position with current ratio of 3.93642704415212. • The company has a high promoter holding of 51.94%. Quarterly Result (All Figures in Cr.) PARTICULARS Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Net Sales 2495.03 2203.92 1823.38 1689.83 1908.17 Total Expenditure 1399.06 1366.34 1214.12 1280.41 1419.47 Operating Profit 1095.97 837.58 609.26 409.42 488.7 Other Income 50.51 89.99 79.25 116.34 66.15 Interest 0.04 0.1 0.13 0.11 0.18 Depreciation 80.75 83.42 85.48 86.54 86.63 Exceptional Items 0 0 0 0 0 Profit Before Tax 1065.69 844.05 602.9 439.11 468.04 Tax 182.73 152.44 116.05 128.21 149.25 Profit After Tax 882.96 691.61 486.85 310.9 318.79 Adjusted EPS (Rs) 33.26 26.05 18.34 11.71 12.01 Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.) PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Net Sales 3815.94 4879...